Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients

Corine H. GeurtsvanKessel; Daryl Geers; Katharina S. Schmitz; Anna Z. Mykytyn; Mart M. Lamers; Susanne Bogers; Lennert Gommers; Roos S.G. Sablerolles; Nella N. Nieuwkoop; Laurine C. Rijsbergen; Laura L.A. van Dijk; Janet de Wilde; Kimberly Alblas; Tim I. Breugem; Bart J.A. Rijnders; Herbert de Jager; Daniela Weiskopf; P. Hugo M. van der Kuy; Alessandro Sette; Marion P.G. Koopmans; Alba Grifoni; Bart L. Haagmans; Rory D. de Vries.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21268416

Documentos relacionados

  1. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients.
  2. T cell responses to SARS-CoV-2 spike cross-recognize Omicron.
  3. Memory CD8<sup>+</sup> T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination.
  4. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.
  5. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
  6. Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
  7. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron.
  8. Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.
  9. Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants.
  10. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.